What is REGN's current stock price?

REGN is currently trading at $772.03 with a daily change of -1.22%. Visit StocksRunner for live updates.

What are REGN stock's key strengths?

REGN current strengths include: Earnings are forecast to grow, Upgraded on attractively valued. These are updated in real time by the StocksRunner IQ algorithm.

What are the risks associated with REGN stock?

Current risk factors for REGN include: Low. Risk levels are assessed by StocksRunner based on volatility, sector strength, volume, and investor confidence.

What is REGN's current StocksRunner IQ Score?

REGN current StocksRunner IQ Score is: Strong Buy. This score reflects aggregated earnings data, news sentiment, analyst ratings, and market momentum as of the latest update.

What factors influence REGN's StocksRunner IQ Score?

REGN StocksRunner IQ Score is a composite Credibility Score that weighs: quarterly earnings results vs. analyst expectations, breaking news sentiment and headline credibility, Wall Street analyst price target consensus, trading volume and price momentum, and sector-level risk indicators. All factors are aggregated in real time.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

REGN Stock Analysis & IQ Rating | Regeneron Pharmaceuticals

Q: Should I buy REGN stock right now?

StocksRunner does not provide personalized investment advice. Our IQ Credibility Score for REGN aggregates analyst sentiment, earnings performance, and news momentum to help you make an informed decision. The current IQ signal is: Strong Buy. Always consider your own risk tolerance and consult a financial advisor before investing.

Q: What does a Strong Buy rating mean for REGN?

A Strong Buy rating on StocksRunner indicates that the aggregated IQ score — drawing from earnings beats, analyst upgrades, and positive news sentiment — reflects high confidence in REGN near-term growth potential. It is the strongest signal in the StocksRunner IQ rating scale.

REGN

Regeneron Pharmaceuticals

$772.03

-$9.57 | -1.22%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$821.11

MKT CAP

$81.62B

52W Low

$476.49

VOL

$471.44K

P/E Ratio

18.43

AVG VOL

$764.26K

RSI

49.42

TREND

Sideways

REGN Stock IQ

Login to see Regeneron Pharmaceuticals (REGN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

REGN Target Price

Login to display

Strengths

REGN Rewards

Earnings are forecast to grow

REGN Rewards

Upgraded on attractively valued

REGN Price Performance

$754.91 (+2.27%)

$746.8 (+3.38%)

$572.6 (+34.83%)

$634.14 (+21.74%)

1year

6month

3month

1month

REGN Analysts Opinion

Overall standing based on market and analyst consensus. menu Hover over the category for more information

REGN Analysts opinion is positive but there was a setback from the past 3 months

REGN Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

80%

Consensus Rating

100%

Buy
Opinion

0%

Trend
Score

50%

Potential
Score

REGN Street Sentiment is extremely bullish and have positive views on the near-term outlook

REGN Risk Level

REGN has Low risk level

Low

LOW

HIGH

REGN Performance Sentiment

Sentiments overview associated with events and the stock performance

80%

Positive

16 out of 20
events present

15%

Negative

3 out of 20
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support Price

$741.45

Resistance Price

$812.27

Current Price Range

$781.60

$741.45

$812.27

Show methods +

Analyst Consensus

Recent Upgrades and Downgrades

100%

Consensus Rating

STRONG BUY

11

Buy

0

Hold

0

Sell

Date

Action

Rating

Firm

Mar 07, 2026

Initiate

Overweight

Barclays

Mar 06, 2026

Initiate

Overweight

Barclays

Mar 06, 2026

Upgrade

Outperform

Oppenheimer

Jan 09, 2026

Upgrade

Buy

Zacks

Jan 07, 2026

Upgrade

Buy

B of A Securities

Runners Also Watch

Close Price

Change

SNY

Sanofi

43.97

-0.86%

NVS

Novartis AG

161.59

-0.73%

TEVA

Teva Pharma

31.52

+0.06%

OPK

Opko Health

1.19

-1.65%

SCYX

SCYNEXIS

0.90

+4.59%

REGN Latest Analysis +

Price Over Earnings Overview: Regeneron Pharmaceuticals. In the current market session Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stock price is at $773.20 after a 1.07% decrease. However over the past month the company'.s stock went up by 2.42% and in the past year by 12.09%. Shareholders might be interested in knowing whether the stock is overvalued even if the company is not performing up to par in the current session. Evaluating Regeneron Pharmaceuticals P/E in Comparison to Its PeersT

Tue Mar 10, 2026

$772.03 | -1.22%

Potential

Regeneron Pharmaceuticals Inc. (REGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript.

Tue Mar 10, 2026

$772.03 | -1.22%

Activity

Regeneron-Licensed Obesity Drug Olatorepatide Shows Positive Results In Phase 3 Trial . (RTTNews) - Regeneron Pharmaceuticals said olatorepatide an investigational obesity treatment it licensed from Hansoh Pharmaceutical Group delivered positive Phase 3 trial results in Chinese patients with obesity or overweight.

Mon Mar 9, 2026

$781.60 | +2.86%

Activity

This Regeneron Pharmaceuticals Analyst Begins Coverage On A ish Note. Here Are Top 5 Initiations For Friday. Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes including upgrades downgrades and initiations please see our analyst ratings page.Oppenheimer analyst Brian Nagel initiated coverage on Motorcar Parts of America Inc (NASDAQ:MPAA) with an Outperform rating and announced a price target of $18. Motorcar Parts of America share

Fri Mar 6, 2026

$759.86 | -0.66%

Rating

Barclays initiates Regeneron stock with Overweight on Dupixent growth.

Fri Mar 6, 2026

$759.86 | -0.66%

Rating

Atavistik Bio Closes $40 Million Series B Extension for Advancement of its Pipeline Bringing Total Round Proceeds to $160 Million. Series B funds will enable clinical development of ATV-1601 an oral allosteric AKT1-selective inhibitor for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and the advancement of its JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms (MPNs) through clinical proof of conceptRA Capital Management joins Atavistik Bio'.s syndi

Thu Mar 5, 2026

$764.93 | -2.87%

Activity

P/E Ratio Insights for Regeneron Pharmaceuticals. In the current market session Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stock price is at $780.00 after a 0.95% drop. However over the past month the company'.s stock spiked by 1.61% and in the past year by 12.75%. Shareholders might be interested in knowing whether the stock is overvalued even if the company is not performing up to par in the current session. Comparing Regeneron Pharmaceuticals P/E Against Its PeersThe P/E ratio is used b

Wed Mar 4, 2026

$787.50 | +2.72%

Momentum

Regeneron Pharmaceuticals Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript.

Wed Mar 4, 2026

$787.50 | +2.72%

Activity

Why Dupixent Keeps Regeneron A Top Big Pharma Pick.

Fri Feb 27, 2026

$781.67 | +1.41%

Potential

FDA Accepts Regeneron (REGN) BLA for Garetosmab Under Priority Review. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best value stocks to buy now. On February 19 Regeneron Pharmaceuticals announced that the FDA accepted its BLA for garetosmab for Priority Review. This investigational monoclonal antibody is designed to treat adults with fibrodysplasia ossificans progressiva/FOP which is an ultra-rare and devastating genetic disorder where muscles and [….]

Tue Feb 24, 2026

$772.19 | -1.89%

Activity

FAQ About REGN Stock Insights

What is REGN current stock price?

What are REGN stock strengths?

What is REGN Risk Level?

What is REGN market cap and volume?

What is REGN current Stock IQ?

Should I buy REGN stock right now?

Is REGN a Strong Buy right now?

What does a 'Strong Buy' rating mean for REGN?

What does a 'Strong Sell' rating mean for REGN?

What factors influence REGN's Stock IQ?

Explore our REGN Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored REGN Stock Strategies
Effective Risk Management

FIND US ON

Receive our REGN Daily Alerts

Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

REGN

Regeneron Pharmaceuticals

Set Alerts

Current Price

$772.03

-$9.57 | -1.22%

52W High

$821.11

MKT CAP

$81.62B

52W Low

$476.49

VOL

$471.44K

P/E Ratio

18.43

AVG VOL

$764.26K

RSI

49.42

TREND

Sideways

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Runners Also Watch

Symbol

Close

Change

SNY

Sanofi

43.97

-0.86%

NVS

Novartis AG

161.59

-0.73%

TEVA

Teva Pharma

31.52

+0.06%

OPK

Opko Health

1.19

-1.65%

SCYX

SCYNEXIS

0.90

+4.59%

REGN Price Performance

$754.91 (+2.27%)

$746.8 (+3.38%)

$572.6 (+34.83%)

$634.14 (+21.74%)

1year

6month

3month

1month

REGN Analysts Opinion

Overall standing per market and analyst expectations. menu Hover over the category for more information

REGN Analysts opinion is positive but there was a setback from the past 3 months

REGN Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

80%

Consensus Rating

100%

Buy
Opinion

0%

Trend
Score

50%

Potential
Score

REGN Street Sentiment is extremely bullish and have positive views on the near-term outlook

REGN Risk Level

REGN has Low risk level

Low

LOW

HIGH

REGN Performance Sentiment

Sentiments overview associated with events and the stock performance.

80%

Positive

16 out of 20
events present

15%

Negative

3 out of 20
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support Price

$741.45

Resistance Price

$812.27

Current Price Range

$781.60

$741.45

$812.27

Show methods +

Latest Analyst Actions

Overall Wall Street Rating

100%

Consensus Rating

STRONG BUY

11

Buy

0

Hold

0

Sell

Date

Action

Rating

Firm

Mar 07, 2026

Initiate

Overweight

Barclays

Mar 06, 2026

Initiate

Overweight

Barclays

Mar 06, 2026

Upgrade

Outperform

Oppenheimer

Jan 09, 2026

Upgrade

Buy

Zacks

Jan 07, 2026

Upgrade

Buy

B of A Securities

Jan 07, 2026

Upgrade

Buy

BofA

REGN Stock IQ

Login to unlock Regeneron Pharmaceuticals (REGN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Target Price

Login to display

Stock Insights

Strengths

REGN Rewards

Earnings are forecast to grow

REGN Rewards

Upgraded on attractively valued

REGN Latest Analysis

Price Over Earnings Overview: Regeneron Pharmaceuticals. In the current market session Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stock price is at $773.20 after a 1.07% decrease. However over the past month the company'.s stock went up by 2.42% and in the past year by 12.09%. Shareholders might be interested in knowing whether the stock is overvalued even if the company is not performing up to par in the current session. Evaluating Regeneron Pharmaceuticals P/E in Comparison to Its PeersT

Tue Mar 10, 2026

$772.03 | -1.22%

Potential

Regeneron Pharmaceuticals Inc. (REGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript.

Tue Mar 10, 2026

$772.03 | -1.22%

Activity

Regeneron-Licensed Obesity Drug Olatorepatide Shows Positive Results In Phase 3 Trial . (RTTNews) - Regeneron Pharmaceuticals said olatorepatide an investigational obesity treatment it licensed from Hansoh Pharmaceutical Group delivered positive Phase 3 trial results in Chinese patients with obesity or overweight.

Mon Mar 9, 2026

$781.60 | +2.86%

Activity

This Regeneron Pharmaceuticals Analyst Begins Coverage On A ish Note. Here Are Top 5 Initiations For Friday. Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes including upgrades downgrades and initiations please see our analyst ratings page.Oppenheimer analyst Brian Nagel initiated coverage on Motorcar Parts of America Inc (NASDAQ:MPAA) with an Outperform rating and announced a price target of $18. Motorcar Parts of America share

Fri Mar 6, 2026

$759.86 | -0.66%

Rating

Barclays initiates Regeneron stock with Overweight on Dupixent growth.

Fri Mar 6, 2026

$759.86 | -0.66%

Rating

Atavistik Bio Closes $40 Million Series B Extension for Advancement of its Pipeline Bringing Total Round Proceeds to $160 Million. Series B funds will enable clinical development of ATV-1601 an oral allosteric AKT1-selective inhibitor for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and the advancement of its JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms (MPNs) through clinical proof of conceptRA Capital Management joins Atavistik Bio'.s syndi

Thu Mar 5, 2026

$764.93 | -2.87%

Activity

P/E Ratio Insights for Regeneron Pharmaceuticals. In the current market session Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stock price is at $780.00 after a 0.95% drop. However over the past month the company'.s stock spiked by 1.61% and in the past year by 12.75%. Shareholders might be interested in knowing whether the stock is overvalued even if the company is not performing up to par in the current session. Comparing Regeneron Pharmaceuticals P/E Against Its PeersThe P/E ratio is used b

Wed Mar 4, 2026

$787.50 | +2.72%

Momentum

Discover REGN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of REGN. We're here to help you make informed investment decisions today.

FIND US ON

Receive our REGN Daily Alerts

Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

REGN Stock trends

REGN Stock performance

REGN Stock analysis

REGN investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing REGN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing REGN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

REGN Stock Analysis & IQ Rating | Regeneron Pharmaceuticals

REGN Stock IQ

REGN Target Price

REGN Analysts Opinion

REGN Street Sentiment

REGN Risk Level

REGN Performance Sentiment

Key Price Levels

Analyst Consensus

Explore our REGN Stock insights

Receive our REGN Daily Alerts

REGN Street Sentiment

REGN Risk Level

Key Price Levels

Latest Analyst Actions

Discover REGN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of REGN. We're here to help you make informed investment decisions today.

Receive our REGN Daily Alerts

REGN Alerts